ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2625

SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort

Mohammed Omair1, Edward C. Keystone2, VP Bykerk3, Boulos Haraoui4, Gilles Boire5, J Carter Thorne3, Janet E. Pope6, Daming Lin7, Carol Hitchon8 and Pooneh S.Akhavan9, 1Rheumatology, Mount Sinai hospital, Toronto, ON, Canada, 2University of Toronto/Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 5Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 6St. Joseph's Health Care, London, ON, Canada, 7mount Sinai Hospital, Toronto, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9mount sinai hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Prognostic factors and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

To compare the sensitivity of the EULAR and SDAI50 response measures (RMs) and their impact on future response to treatment in patients with early rheumatoid arthritis (RA). 

Methods: Biologic naïve RA patients from the Canadian early ArThritis CoHort (CATCH) who had baseline, 3 and 6 months complete data were evaluated. Kappa statistics & Spearman correlation were used to assess the correlation between the EULAR and SDAI50 RMs. The RMs at 3 months were also compared for their ability to predict low disease state (LDAS) or remission (REM) at 6months.

Results: A total of 419 patients were evaluated. Of those, 198 (47.2%) and 206 (49.1%) patients failed to achieve a EULAR and SDAI50 RMs respectively. A strong correlation was observed between the EULAR and SDAI50 RMs with a Kappa of 0.66 (95% CI 0.58- 0.73) and Spearman coefficient of 0.66 (p <0.0001).  Throughout the range of disease activity, the SDAI50 response was shown to be more stringent  than the EULAR response. Multivariate linear regression analysis demonstrated that SDAI50 at 3 months had a more significant impact on achieving low disease state or remission at 6 months compare to the EULAR response.

Conclusion: Our results suggest there is a strong overall correlation between the EULAR and SDAI50 RMs however a minority of patients can be identified with discordant RMs at the two ends of disease activity spectrum at baseline. Nevertheless the SDAI response at 3 month was a better predictor of outcomes at 6 months than the EULAR response.


Disclosure: M. Omair, Pfizer Inc, 2,Roche Pharmaceuticals, 9,newbridge, 9,Bristol-Myers Squibb, 9; E. C. Keystone, Janssen Inc., 2,Abbott/AbbVie, 5,Amgen, 2,Bristol-Myers Squibb, 5,Janssen Inc., 5,Hoffmann-La Roche, Inc., 5,Janssen Inc., 2,Janssen Inc., 5,Merck Pharmaceuticals, 5,Merck Pharmaceuticals, 5,Pfizer Pharmaceuticals, 5,Pfizer Pharmaceuticals, 5; V. Bykerk, None; B. Haraoui, Abbott, Amgen, BMS, Janssen, Pfizer, Roche and UCB Pharma, 2,Abbott, Amgen, BMS, Janssen, Pfizer, Roche and UCB Pharma, 5,Abbott, Amgen, BMS, Janssen, Pfizer, Roche and UCB Pharma, 8; G. Boire, None; J. C. Thorne, Amgen, Canada, 5; J. E. Pope, None; D. Lin, None; C. Hitchon, None; P. S.Akhavan, None.

To cite this abstract in AMA style:

Omair M, Keystone EC, Bykerk V, Haraoui B, Boire G, Thorne JC, Pope JE, Lin D, Hitchon C, S.Akhavan P. SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/sdai-50-is-more-stringent-than-the-eular-response-measure-and-a-better-predictor-of-low-disease-stateremission-in-early-rheumatoid-arthritis-results-from-an-early-arthritis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sdai-50-is-more-stringent-than-the-eular-response-measure-and-a-better-predictor-of-low-disease-stateremission-in-early-rheumatoid-arthritis-results-from-an-early-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology